May 07, 2025

FDA Approves Low-Dose Chlorthalidone Tablet

The FDA has approved HemiClor, a 12.5-mg chlorthalidone tablet, providing patients with a low-dose option.

Conexiant

May 06, 2025

FDA Approves TAVR Platform for Asymptomatic AS

The FDA has approved the SAPIEN 3 TAVR platform for patients with asymptomatic severe aortic stenosis based on data from the EARLY TAVR trial.

Conexiant

May 06, 2025

Anemia Linked to Hidden Heart Strain in RA

A new study found that 1 in 3 rheumatoid arthritis patients with normal heart function on standard tests had hidden heart strain detectable only through advanced imaging, with anemia emerging as the strongest predictor.

Conexiant

May 06, 2025

Weight Loss, Hypokalemia Reveal Pituitary Cushing’s Disease

A 75-year-old woman with severe weight loss and low potassium was diagnosed with pituitary Cushing’s disease, challenging assumptions about how the condition typically presents.

Conexiant

May 05, 2025

True Heart Age Beyond Birthdays

New research uses cardiac MRI to calculate "functional heart age," showing obesity and other risk factors can age the heart by decades.

Conexiant

May 01, 2025

Modifiable Risk Factors Linked to Sudden Cardiac Arrest Incidence

A UK Biobank analysis identified 56 modifiable risk factors for sudden cardiac arrest; lifestyle improvements alone could prevent up to 18% of cases, with a total prevention potential of 63%.

Conexiant

April 30, 2025

New Phase III Data: Sotatercept for PAH

Sotatercept reduced the composite risk of death, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension by nearly 75% compared with placebo in high-risk patients in a phase III trial.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 29, 2025

New Drug Tames Resistant High Blood Pressure

Lorundrostat reduces blood pressure significantly in patients with treatment-resistant hypertension by targeting aldosterone production.

Conexiant